高级检索
当前位置: 首页 > 详情页

Clinical course of patients on maintenance hemodialysis and COVID-19: a retrospective longitudinal study

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Nephrology, Union Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430033, Hubei, China. [2]Department of Surgery,Tongji Hosptial,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China. [3]Department and Institute of Urology,Tongji Hosptial,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China. [4]Tongji multidisciplinary Team for Treating COVID-19 (TTTC),Tongji Hosptial,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China.
出处:
ISSN:

关键词: maintenance hemodialysis patients COVID-19 clinical features outcome SARS-COV-2

摘要:
Coronavirus Disease 2019 (COVID-19) emerges as a global pandemic and there is a lack of evidence about the clinical course and outcome of patients on maintenance hemodialysis (MHD). Here we conducted a retrospective longitudinal study aimed to analyze the clinical features and outcome of MHD patients hospitalized with COVID-19. Of 3126 inpatients with COVID-19 at 3 Branches of Wuhan Tongji Hospital from Jan 18th to Mar 9th, 2020, 19 patients were undergoing maintenance hemodialysis. Among the 19 MHD patients with COVID-19, 6 patients (31.6%) died, and 13 patients (68.4%) were able to be discharged. Baseline characteristics, clinical courses, laboratory findings, and dynamic trajectories of major laboratory markers were compared between survivors and nonsurvivors. According to our findings, MHD patients with COVID-19 who experienced non-surviving outcome had more elevated CRP, IL6 and procalcitonin as well as fibrinogen levels at various points compared to survivors. Thus the dysregulation of immune response as well as coagulation abnormalities might be highly involved in the pathological process of COVID-19, contributing to the poor prognosis in MHD patients.

基金:

基金编号: 81874065 81500565 2018ZX10723204-003

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2019]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Department of Nephrology, Union Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430033, Hubei, China.
通讯作者:
通讯机构: [2]Department of Surgery,Tongji Hosptial,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China. [4]Tongji multidisciplinary Team for Treating COVID-19 (TTTC),Tongji Hosptial,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei,China. [*1]Department of Surgery,National Medical Center for Major Public Health Events,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Jiefang avenue1095,Wuhan,China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:432 今日访问量:0 总访问量:413 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)